We've long been able to sequence whole, small genomes, yet the Human Genome Project only completed sequencing the human genome in 2003. Since then, the world has seen even more rapid and widespread use of whole genome information to understand how humans and other organisms work, but the genome is far from the whole story. The genome is a blueprint that defines how to make proteins and other functional molecules that are important to life, but at any given time or place in the body, only a small portion of genes are active. That is, only a portion of genes are being transcribed into messenger RNA ("expressed") at once. Gene expression profiling gives a picture of cell activity at a given moment.
Two well-known expression profiling methods are the northern blot and DNA microarrays. They both start by collecting a sample of RNA that is isolated and purified. For northern blot, the sample is stratified using electrophoresis and transferred to a blotting membrane. The membrane is then treated with complementary RNA sequences ("probes") that have been marked with radioactive isotopes. The probes bind to the sample RNA on the membrane and the density of the bound probes can be read via X-ray. For DNA microarray, the sample RNA itself is tagged and applied to a plastic chip that has fixed RNA probes of many types. The density of every type of bound sample RNA can then be read via laser.
Expression profiles provide computational biologists with information they can use to learn far more about how organisms work than can be understood from the genome alone. This knowledge, such as how an organism reacts to temperature change or drug treatments, could be the key to unlocking important insights in biology and medicine, and as always, the future looks pretty exciting.
-Finn Kuusisto nosis of cancer patients. One way this can be achieved is by detecting signs of cancer at its early stages. Recently, non-invasive approaches and technologies to sample genetic material from cancer cells have emerged. Among them is the "liquid biopsy," which aims to collect circulating cell-free DNA from body fluids such as blood plasma. The potential to use non-invasive sampling techniques to screen for cancer is exciting, but new computational approaches are required to make reliable inferences about the data generated. A sample obtained from a biopsy will likely contain a greater proportion of tumor cells/ DNA to normal cells/DNA than a sample obtained using non-invasive methods. As such, my current research is focused on developing computational and statistical learning methods to reliably detect signs of malignant tissue, and finding evidence of genomic abnormalities in samples with low cancer signal and distinguishing them from errors inherent in next-generation sequencing and the natural variation between individuals.
This field of research has an exciting future and Cambridge is a great place to study. It has a strong reputation in mathematics and medical science, along with a history, beauty, and welcoming collegiate system. In the coming years, with the relentless emergence of new technologies and new computational approaches, I hope we can deliver on the promise of personalized medicine to optimize the prevention and treatment of disease for each individual.
Biography
Sam Abujudeh is a Ph.D. student at the Cancer Research UK Cambridge Institute. His interests lie with applying statistical learning methods to high throughput sequencing data to detect cancerous tissue. 1977 1995 
Northern Blot DNA Microarray

Developed
